Last reviewed · How we verify

NCT03699800

Graphomotor Intervention Program for Handwriting Difficulties Prevention in School-Age

Completed NA Last updated 27 March 2020
What this trial tests

NA trial testing Graphomotor intervention program in Typical Development in 47 participants. Completed in 31 December 2019.

Timeline
15 October 2018
Primary endpoint
31 December 2019
31 December 2019

Quick facts

Lead sponsorUniversity of Évora
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment47
Start date15 October 2018
Primary completion31 December 2019
Estimated completion31 December 2019
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

University of Évora

Who can join

Adults 7 to 7, any sex, with Typical Development or Risk of Dysgraphia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

12-30% of children present handwriting difficulties, which has negative repercussions on their school career. For this reason, it is fundamental to bet on their prevention. The aim of present study is to examine the effects of a graphomotor intervention program on quality and speed of handwriting in second-grade children. This experimental study is a randomized controlled trial. The program will run for 8 weeks (2 sessions/week of 30 minutes), followed by 6 months of follow-up without intervention. Participants will be assessed 1) at baseline, 2) at the end of the program, and 3) after the follow-up. Participants will be randomly allocated to two groups: experimental group (graphomotor intervention program) and control group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Graphomotor intervention program

Trials testing the same drug.

Other recruiting trials for Typical Development

Currently open trials in the same condition.

Other University of Évora trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03699800.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing